Literature DB >> 1862109

Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction.

D G Gilliland1, K L Blanchard, J Levy, S Perrin, H F Bunn.   

Abstract

The myeloproliferative syndromes are acquired disorders of hematopoiesis that provide insights into the transition from somatic cell mutation to neoplasia. The clonal origin of specific blood cells can be assessed in patients with X chromosome-linked polymorphisms, taking advantage of random inactivation of the X chromosome. We have adapted the PCR for determination of clonality on as few as 100 cells, including individual colonies grown in culture. Amplifying a polymorphic portion of the X chromosome-linked phosphoglycerate kinase (PGK) gene after selective digestion of the active X chromosome with a methylation-sensitive restriction enzyme gave results fully concordant with standard Southern blotting of DNA samples from normal (polyclonal) polymorphonuclear cells (PMN) as well as clonal PMN from patients with myelodysplastic syndrome and polycythemia vera (PCV). We have used this technique to demonstrate heterogeneity of lineage involvement in patients with PCV. The same clinical phenotype may arise from clonal proliferation of different hematopoietic progenitors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1862109      PMCID: PMC52186          DOI: 10.1073/pnas.88.15.6848

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Essential thrombocythemia in two sisters originating from different stem cell levels.

Authors:  J W Janssen; B R Anger; H G Drexler; C R Bartram; H Heimpel
Journal:  Blood       Date:  1990-04-15       Impact factor: 22.113

2.  An improved method for prenatal diagnosis of genetic diseases by analysis of amplified DNA sequences. Application to hemophilia A.

Authors:  S C Kogan; M Doherty; J Gitschier
Journal:  N Engl J Med       Date:  1987-10-15       Impact factor: 91.245

3.  Clonal origin of chronic myelocytic leukemia in man.

Authors:  P J Fialkow; S M Gartler; A Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1967-10       Impact factor: 11.205

4.  Polymorphic DNA region adjacent to the 5' end of the human insulin gene.

Authors:  G I Bell; J H Karam; W J Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

5.  Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; A P Feinberg
Journal:  Science       Date:  1985-02-08       Impact factor: 47.728

6.  Evidence for a multistep pathogenesis of a myelodysplastic syndrome.

Authors:  W H Raskind; N Tirumali; R Jacobson; J Singer; P J Fialkow
Journal:  Blood       Date:  1984-06       Impact factor: 22.113

7.  Polycythemia vera. The in vitro response of normal and abnormal stem cell lines to erythropoietin.

Authors:  J F Prchal; J W Adamson; S Murphy; L Steinmann; P J Fialkow
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

8.  Polycythemia vera. Further in vitro studies of hematopoietic regulation.

Authors:  J W Adamson; J W Singer; P Catalano; S Murphy; N Lin; L Steinmann; C Ernst; P J Fialkow
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

9.  Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell.

Authors:  P J Fialkow; G B Faguet; R J Jacobson; K Vaidya; S Murphy
Journal:  Blood       Date:  1981-11       Impact factor: 22.113

10.  Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms.

Authors:  A Tefferi; S N Thibodeau; L A Solberg
Journal:  Blood       Date:  1990-05-01       Impact factor: 22.113

View more
  40 in total

1.  Phyllodes Tumor of the Breast: Pathology, Histogenesis, Diagnosis, and Treatment.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

Review 2.  Basic sciences of the myeloproliferative diseases: pathogenic mechanisms of ET and PV.

Authors:  Rosemary E Gale
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Preoperative Discrimination of Fibroadenoma Which Is Clinically and Cytologically Indistinguishable from Breast Carcinoma through Clonal Analysis of Fine Needle Aspirate of Tumor: Report of a Case.

Authors: 
Journal:  Breast Cancer       Date:  1994-07-30       Impact factor: 4.239

Review 4.  Pathogenesis of idiopathic myelofibrosis: role of growth factors.

Authors:  J T Reilly
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

5.  X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.

Authors:  Ross L Levine; Claude Belisle; Martha Wadleigh; David Zahrieh; Stephanie Lee; Pierre Chagnon; D Gary Gilliland; Lambert Busque
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

Review 6.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

Review 7.  Normal and malignant megakaryopoiesis.

Authors:  Qiang Wen; Benjamin Goldenson; John D Crispino
Journal:  Expert Rev Mol Med       Date:  2011-10-21       Impact factor: 5.600

Review 8.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

9.  The PGK-PCR clonality assay (PPCA).

Authors:  L Busque; D G Gilliland
Journal:  Mol Biotechnol       Date:  1996-06       Impact factor: 2.695

10.  A novel Tth111I restriction fragment length polymorphism (RFLP) allows tracing of X-chromosome inactivation in the (Xid) heterozygote.

Authors:  V Shanmugam; V M Chapman; K W Sell; B K Saha
Journal:  Biochem Genet       Date:  1996-02       Impact factor: 1.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.